小智港股覆盤 | 6月8日
今日，港股三大指數集體上漲。截止收盤，恆生指數大漲2.24%，報22014點。國企指數大漲2.84%，報7679點。恆生科技指數大漲4.76%，報4818點。市場約1062只個股上漲，629只個股下跌。成交額突破1840.28億港幣，和昨天同期相比增長31.37%。南下資金淨流出9077.18萬港幣。
盤面上，互聯網醫療板塊全線走強。阿裏健康漲超11%；鷹瞳科技-B漲超6%；平安好醫生、醫渡科技等多股漲超5%；醫脈通漲超3%。大和降阿裏健康目標價72%至4.2港元，下調至“持有”評級；大和降平安好醫生目標價9%至22.75港元，維持“買入”評級。
CRO板塊暴漲。泰格醫藥漲超10%；昭衍新藥、藥明康德、藥明生物等多股漲超8%；康龍化成漲超7%。泰格醫藥升7%，前5個月IND處於相對高位，機構指公司在手訂單飽滿高增長確定性強；昭衍新藥因期權獲行使發行2.1萬股股份；藥明康德：A股將於6月9日派現金紅利每股0.5174元人民幣；藥明生物拉昇8%，前四月新簽訂單數超指引，強調Omicron擾動對業務影響有限。
生物科技板塊全線走強。百濟神州漲超13%；榮昌生物-B漲超12%；信達生物漲超10%；康諾亞-B、諾誠健華-B等多股漲超9%。百濟神州(6160.HK)大漲近11%，獲北水連續3日加倉；榮昌生物-B早盤再漲超16%，維迪西妥單抗治療尿路上皮癌最新數據亮眼；招銀國際降信達生物目標價至58.32港元，維持“買入”評級；康諾亞-B盤中漲近10%，抗IL-4Rα單抗擬納入突破性治療品種。
燃氣板塊走弱。中油燃氣、香港中華煤氣等多股跌超2%；華潤燃氣(一百)、中國燃氣等多股跌超1%。
海運板塊走弱。榮豐億控股跌超6%；永豐集團控股跌超3%；太平洋航運、東方海外國際、珠江船務等多股跌超1%。
電力板塊走弱。華能國際電力股份、華潤電力、普星能量等多股跌超3%；大唐發電、粵豐環保等多股跌超2%。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
